AGP Executive Report
Last update: an hour agoCancer R&D: Akeso’s ivonescimab plus chemotherapy showed a statistically significant overall survival gain in China’s HARMONi-6 Phase III trial for first-line advanced squamous NSCLC, extending median survival to 27.9 months vs 23.7 with tislelizumab plus chemo. Public Health Systems: China’s community-based smoking cessation push in Shenzhen is scaling via digital follow-ups across 1,000+ health centers, screening 13M+ first visits and supporting 10,000+ quit attempts. Regulatory Watch: US FDA flagged serious manufacturing, maintenance and data integrity lapses at Dabur India’s plant in Dadra & Nagar Haveli, citing contamination risks and alleged record falsification. Healthcare Diplomacy: China’s PLA Navy hospital ship Silk Road Ark sailed on a South China Sea medical mission, offering consultations, traditional Chinese medicine physiotherapy and surgeries. Child & Minor Protection: China’s civil affairs ministry issued new rules for tailored mental health and support services for minors, including safety checks at protection facilities. Ebola Preparedness: A new report says Ebola response is being strained by reduced US foreign aid support after USAID was dismantled.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
